Pfizer and Moderna are testing their vaccines against coronavirus for vsee if they work against the new strain that has been identified in the UK and other countries, according to company announcements published on CNN.
“Based on data to date, we expect Moderna vaccine-induced immunity to protect against newly described variants in the UK; we will additional testing in the coming weeks to confirm this expectation“, picks up the Moderna document.
For its part, Pfizer has informed the US media that it is now “generating data” on how well blood samples from people immunized with their vaccine “may be able to neutralize the new UK strain.”
Meanwhile, BioNTech, a contributing partner of Pfizer, has announced that it could produce in a period of six weeks a modifying your vaccine to accommodate this virus mutation. “But that is a purely technical consideration,” BioNTech chief Ugur Sahin commented on Tuesday.
The company leader has specified that it is not only about technical issues, but also how the regulatory authorities would qualify this modification. In any case, it has ensured that it is “very likely” that the vaccine that has already been produced will also work against the new variant. “The platform of the previous vaccine would not be affected if it were developed further,” added BioNTech medical director and co-founder Ozlem Tureci.
In this case, the question would be to what extent the authorities will accept as a basis the safety and efficacy data already presented for the current vaccine, despite it being a new modification. This, in turn, would influence the length of a possible approval process.
On the other hand, the executive director of BioNTech, Sean Marett, has advanced that the first deliveries of the vaccine in the European Union can start this wednesday. In addition, he has detailed that by the end of this year European countries could receive up to 12.5 million doses.
The doses are currently stored in the plant of Pfizer, BioNTech’s partner in the United States, in Puurs (Belgium). This is where the raw materials, which are manufactured in BioNTech’s various production facilities, are processed and filled.
As explained by BioNTech’s CFO, Sierk Poeting, doses should be in every EU member state on Saturday so that vaccinations can begin on Sunday. That is the forecast that the European Commission also has.
The chairman of the German COVID-19 body, the Robert Koch Institute (RKI), Lothar Wieler, has commented that the new variant is apparently much more common in the UK than other strains. “That could be because it is more infectious, but it does not have to be this way. We still cannot clearly assess the importance of the variant for what is happening,” he said.
Regarding the importance of the variant in the vaccine, Wieler has argued that “all the data known so far suggest that the protection provided by vaccination is not restricted if this variant is extended further.”
Digsmak is a news publisher with over 12 years of reporting experiance; and have published in many industry leading publications and news sites.